Metformin treatment reduces ovarian cytochrome P-450c17{alpha} response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome

Antonio la Marca1, Thomas Obinchemti Egbe2, Giuseppe Morgante1, Tiziana Paglia1, Antonio Ciani3 and Vincenzo De Leo1,4

1 Department Obstetrics and Gynaecology, University of Siena, Policlinico Le Scotte, 53100 Siena, 2 Hospital General de Douala, Cameroun and 3 University of Catania, Italy


    Abstract
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
It has recently been proposed that hyperinsulinaemic insulin resistance and increased ovarian cytochrome P-450c17{alpha} activity, two features of the polycystic ovary syndrome (PCOS), are pathogenetically linked. The aim of the present study was to test the hypothesis of the linkage between hyperinsulinaemia and supranormal activity of cytochrome P-450c17{alpha} using the human chorionic gonadotrophin (HCG) challenge, which is a more direct ovarian stimulus than gonadotrophin-releasing hormone (GnRH) in detecting modifications in ovarian steroidogenesis. Eleven women with insulin resistance-related PCOS were studied. HCG (10 000 IU) was given i.m., and blood samples were obtained 0, 8, 12, 16 and 24 h thereafter. Next day, metformin was given at a dose of 500 mg three times a day for 30–32 days, at which time the pretreatment study was repeated. Two women ovulated after metformin treatment. The administration of metformin was associated with a decrease in area under the curve for insulin during a 2h, 75g oral glucose tolerance test, in plasma free testosterone concentrations and an increase in plasma sex hormone binding globulin concentration. The plasma 17-hydroxyprogesterone response to HCG was significantly lower after metformin treatment. The present study gives a direct demonstration that metformin leads to a reduction in stimulated ovarian cytochrome P-450c17{alpha} activity in women with polycystic ovary syndrome.

Key words: androgens/HCG/insulin/metformin/17OHP/PCOS


    Introduction
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
It has been recently proposed that hyperinsulinaemic insulin resistance and increased ovarian cytochrome P-450c17{alpha} activity, two features of the polycystic ovary syndrome (PCOS), are pathogenetically linked (Nestler and Jakubowicz, 1996Go).

Cytochrome P-450c17{alpha} is a key enzyme in ovarian androgen steroidogenesis. It has been known for many years that the vast majority of women with PCOS have a supranormal plasma 17-hydroxyprogesterone (17OHP) response and poorer responsiveness of androstenedione to gonadotrophin-releasing hormone (GnRH) administration (Barnes et al., 1989Go; Sahin and Kelestimur, 1997Go), indicating increased ovarian cytochrome P-450c17{alpha} activity.

Insulin resistance and the resulting raised plasma concentrations of insulin are reported to be responsible for high androgen concentrations in PCOS. Indeed there is evidence that insulin stimulates ovarian oestrogen, androgen and progesterone secretion in vitro (Dunaif, 1992Go). Insulin inhibits liver secretion of sex hormone binding globulin (SHBG), increasing the availability of androgens (Nestler et al., 1991Go). Another mechanism of action could be inhibition of liver synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) by insulin, leading to increased availability of insulin-like growth factor-1 (IGF-I) in the ovary (Leroith et al., 1995Go).

Reduction in hyperinsulinaemia in women with PCOS by diazoxide (Nestler et al., 1989Go), a somatostatin analogue (Prelevic et al., 1990Go), and by the insulin sensitizing agent troglitazone (Dunaif et al., 1996Go; Ehrmann et al., 1997aGo) resulted in a significant decrease in baseline androgen concentrations. The somatostatin analogue significantly decreased androstenedione, oestradiol and testosterone responses to GnRH agonist administration; however, 17OHP response was not determined (Prelevic et al., 1990Go).

To test the hypothesis that hyperinsulinaemia stimulates ovarian cytochrome P-450c17{alpha} activity in PCOS, the basal 17OHP concentrations and the plasma 17OHP responses to administration of leuprolide in PCOS women have been measured before and after administration of metformin (Nestler and Jakubowicz, 1996Go).

Metformin, an insulin-sensitizing agent, is normally used to treat non-insulin-dependent diabetes. Its multiple mechanism of action includes inhibition of gluconeogenesis in the liver and stimulation of peripheral uptake of glucose (Bailey, 1992Go; Bailey and Turner, 1996Go).

Interestingly, in another study metformin did not improve hyperinsulinaemia nor did it improve dysregulation of ovarian steroidogenesis as determined by the GnRH test (Ehrmann et al., 1997bGo).

The aim of the present study was to test the hypothesis of a linkage between hyperinsulinaemia and supranormal activity of cytochrome P-450c17{alpha} using the HCG challenge, which is a more direct ovarian stimulus than GnRH in detecting modifications in ovarian steroidogenesis.


    Materials and methods
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Subjects
Eleven women with PCOS were recruited. The clinical diagnosis of PCOS was based on hyperandrogenaemia (plasma free testosterone >34.6 pmol/l) and oligomenorrhoea (fewer than six menstrual periods in the previous year) or amenorrhoea. None of the women had virilization or congenital adrenal hyperplasia (on the basis of normal concentrations of 17OHP). Before treatment, basal hormone concentrations revealed anovulatory cycles, increased serum concentrations of luteinizing hormone (LH), an increased LH/follicle stimulating hormone (FSH) ratio and androstenedione and testosterone concentrations at the upper limits of the normal range.

A baseline ultrasound scan was performed to evaluate the uterus and ovaries. Ultrasonographic diagnosis of PCOS was based on the presence of 10 or more follicles (2–10 mm in diameter) in one or both ovaries. All women were normoprolactinaemic. All had normal thyroid function.

All the women had a fasting insulin concentration of >60 pmol/l and an accumulated insulin concentration (area under the curve for insulin during a 2 h, 75 g oral glucose test; AUCinsulin) of >48 000 pmol/l/min.

Study protocol
The patients were in follicular phase of the menstrual cycle (i.e. plasma concentrations of progesterone <6 nmol/l) when they entered the study.

All patients were studied at 08.00 h after overnight bed rest and fasting. HCG (Profasi, Serono, Rome, Italy) was given i.m., and blood samples were obtained 0, 8, 12, 16 and 24 h thereafter. On the next day, metformin (Metforal; Guidotti, Pisa, Italy) was given at a dose of 500 mg three times a day.

Subjects received metformin for 30–32 days, at which time the pretreatment study was repeated. Spontaneous ovulation was checked by blood samples taken on days 20 and 27 from the beginning of metformin administration. Two women had serum progesterone values in the postovulatory range and were excluded from the study.

Hormone assay
Plasma LH, FSH, oestradiol, testosterone, androstenedione, free testosterone, 17OHP and SHBG were measured by double antibody radioimmunoassay using Radim kits (Rome, Italy) for LH, FSH, Sorin kits (Saluggia, Italy) for androstenedione and testosterone, DPC kits (Los Angeles, CA, USA) for SHBG, free testosterone and 17OHP and Biodata Kits (Rome, Italy) for oestradiol. The samples were assayed in duplicate at two dilutions. All samples from each subject were assayed together. Quality control pools at low, medium and high hormone concentrations were included in each assay. The intra-assay and inter-assay coefficients of variation did not exceed 10 and 15% respectively.

Statistical analysis
To compare the response before and after metformin therapy, hormone basal concentrations, maximum increments (the maximum rise above baseline) and the areas under the curve (cumulative rise above baseline) were compared using paired Student's two-tailed t-test. Areas under the curves above baseline (AUC) were calculated by the trapezoidal method and expressed as nmol/l per unit of time. Differences were considered significant for P < 0.05.


    Results
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Complete data from nine of the 11 women were analysed. Two women ovulated after taking metformin.

The body mass index did not change significantly during the study. Metformin administration led to a significant reduction in AUCinsulin (65 850 ± 11 220 versus 45 900 ± 8700 pmol/l/min; P < 0.05). The administration of metformin was associated with a decrease in plasma free testosterone concentrations (43 ± 4 versus 35 ± 4 pmol/l; P < 0.05), and an increase in plasma SHBG concentrations (64 ± 10 versus 97 ± 15 nmol/l; P < 0.05). There were no statistically significant reductions in plasma androstenedione (12 ± 3 versus 11.4 ± 2.9 nmol/l), testosterone (2.2 ± 0.4 versus 2.1 ± 0.3 nmol/l) and 17OHP (4.1 ± 0.5 versus 3.9 ± 0.4 nmol/l) concentrations after metformin treatment (Table IGo).


View this table:
[in this window]
[in a new window]
 
Table I. Clinical and hormonal data from nine women with polycystic ovary syndrome (PCOS) before and after metformin treatment
 
The plasma 17OHP response to HCG was significantly lower after metformin treatment. The peak serum 17OHP decreased from 16.7 ± 3 to 10.2 ± 2.8 nmol/l; P < 0.05 (delta max 12.6 ± 2.4 versus 6.3 ± 1.9 nmol/l; P < 0.05). The AUC was significantly lower after therapy (152 ± 58 versus 74 ± 31 nmol/l/min; P < 0.05) (Figure 1Go).



View larger version (11K):
[in this window]
[in a new window]
 
Figure 1. Plasma 17-hydroxyprogesterone (17OHP) response to human chorionic gonadotrophin (HCG) after metformin administration. Response after metformin treatment was significantly lower (P < 0.05) than before.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
The results of the present study show that metformin administration in women with PCOS leads to a reduction in ovarian cytochrome P-450c17{alpha} activity, as demonstrated by a significant reduction in the responses of 17OHP to the administration of HCG.

Our results confirmed those obtained previously (Nestler and Jakubowicz, 1996Go). In that report, it was concluded that the metformin-induced insulin reduction was accompanied by a decline in ovarian cytochrome activity. This suggests that increased ovarian cytochrome activity in PCOS women is probably due to stimulation by insulin. This conclusion, however, is supported only in part by their data. The treatment group and the placebo group differed significantly with respect to basal LH plasma concentrations (8.5 ± 2.2 versus 3.7 ± 0.7 IU/l; P < 0.05).

Moreover, metformin administration led to a reduction in LH response to GnRH. The decline in androgen production was attributed to the direct effect of insulin on ovarian enzyme, but it may be also have been due to a reduction in LH response to GnRH.

The HCG test was recently re-evaluated for the diagnosis of ovarian hyperandrogenism (Levrant et al., 1997Go). HCG is essentially an LH analogue which induces a direct stimulation of thecal cell steroidogenesis. It has been shown that the responses of 17OHP, androstenedione and testosterone to HCG in women with functional ovarian hyperandrogenism (defined by androgen excess and an increased 17OHP response to nafarelin) were significantly greater than in normal women. We used the HCG challenge to test the hypothesis that metformin administration leads to a reduction in cytochrome P-450c17{alpha} activity. This avoids problematic statistical corrections with respect to the reduction in LH response to GnRH after metformin administration reported (Nestler and Jakubowicz, 1996Go).

In our study, metformin administration led to an increase in SHBG and to a consequent reduction in free testosterone; however, there was no reduction in total testosterone plasma concentration. On the other hand, a reduction of total testosterone after metformin treatment has been reported (Velazquez, 1997). Only 18% (2/11) of women in our study ovulated spontaneously after metformin therapy compared with published data where values such as 34% (Nestler et al., 1998Go) and 95% (Velazquez et al., 1997Go) are shown. The reasons for these discrepancies are not known, but the results of the HCG stimulation test confirmed those obtained previously (Nestler and Jakubowicz, 1996Go).

Metformin treatment led to a reduction in 17OHP response to HCG administration.

The present study gives a direct demonstration that metformin leads to a reduction in stimulated ovarian cytochrome P-450c17{alpha} activity in women with PCOS.


    Notes
 
4 To whom correspondence should be addressed Back


    References
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Bailey, C.J. (1992) Biguanides and NIDDM. Diabetes Care, 15, 755–772.[Abstract]

Bailey, C.J. and Turner, R.C. (1996) Metformin drug therapy. N. Engl. J. Med., 334, 574–579.[Free Full Text]

Barnes, R.B., Rosenfield, R.L., Burstein, S. and Ehrmann, D.A. (1989) Pituitary–ovarian response to nafarelin testing in the polycystic ovary syndrome. N. Engl. J. Med., 320, 559–565.[Abstract]

Dunaif, A. (1992) Insulin resistance and ovarian hyperandrogenism. Endocrinologist, 2, 248–260.

Dunaif, A., Scott, D., Finegood, D. et al. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 81, 3299–3306.[Abstract]

Ehrmann, D.A., Schneider, D.J., Sobel, B.E. et al. (1997a) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 2108–2116.[Abstract/Free Full Text]

Ehrmann, D.A., Cavaghan, M.K., Imperial, J. et al. (1997b) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 524–530.[Abstract/Free Full Text]

Leroith, D., Werner, H., Beitner-Johnson, D. and Roberts Jr, C.T. (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev., 16, 143–163.[ISI][Medline]

Levrant, S.G., Barnes, R.B. and Rosenfield, R.L. (1997) A pilot study of the human chorionic gonadotrophin test for ovarian hyperandrogenism. Hum. Reprod., 12, 1416–1420.[Abstract]

Nestler, J.E. and Jakubowicz, D.J. (1996) Decreases in ovarian cytochrome P450c17{alpha} activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med., 335, 617–623.[Abstract/Free Full Text]

Nestler, J.E., Barlascini, C.O., Matt, D.W. et al. (1989) Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 68, 1027–1032.[Abstract]

Nestler, J.E., Powers, L.P., Matt, D.W. et al. (1991) A direct effect of hyperinsulinemia on serum sex-hormone binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 72, 83–89.[Abstract]

Nestler, J.E., Jakubowicz, D.J., Evans, W.S. and Pasquali, R. (1998) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med., 338, 1876–1880.[Abstract/Free Full Text]

Prelevic, G.M., Wurzburger M.I., Balint-Peric, L. and Nesic, J.S. (1990) Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet, 336, 900.[ISI][Medline]

Sahin, Y. and Kelestimur, F. (1997) 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17alpha dysregulation. Hum. Reprod., 12, 910–913.[ISI][Medline]

Velazquez, E., Acosta, A. and Mendoza, S.G. (1997) Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet. Gynecol., 90, 392–395.[Abstract/Free Full Text]

Submitted on April 5, 1999; accepted on September 13, 1999.